A new company is responsible for Japanese promotional activities for Actair, Stallergenes Greer’s sublingual immunotherapy ...

In the high-stakes world of drug development, a pill is never just a pill. Every oral drug that reaches the market has passed through a tightly managed series of steps—none more critical, or more ...

Multinational pharmaceutical companies (MNCs) are facing significant challenges in China's vaccine market, as regulatory ...

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with ...

A new European Commission strategy promises to lift life sciences in the region out of a two-decade slump by tackling ...

UK-based contract research, development and manufacturing organization Ingenza has named Nick Challoner as its new chief ...

US-Japan venture capital firm AN Venture Partners has wrapped up its first fund at $200 million, marking one of the largest ...

French biotech MaaT Pharma has signed a licensing and distribution agreement with UK-based Clinigen, positioning the company ...

Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.

The UK government today launched its 10 Year Health Plan for the National Health Service (NHS), promising a "new era." A new ...